Key Takeaways:
- Pipeline Expansion: AbbVie’s $650 million upfront RC148 licensing deal adds a PD-1/VEGF backbone to pair with its ADC portfolio.
- Regulatory Momentum: AbbVie’s FDA and EMA filings for Rinvoq in vitiligo position the drug as a potential first systemic option in a large dermatology market.
- Target Price Path: AbbVie stock could reach $291 by 2028 as the model embeds 8% revenue growth and a 15x P/E.
- Return Math: AbbVie’s $291 target implies 30% upside from the $223 current price, translating to about 10% annualized returns over roughly 3 years if margins and multiple hold.
AbbVie Inc. (ABBV) generates $61 billion of 2025 revenue across immunology, neuroscience, oncology, aesthetics, and eye care and other specialty products through global sales of branded therapies.
Its portfolio spans autoimmune disease, migraine, psychiatry, oncology, and aesthetics, following roughly $16 billion in U.S. Humira erosion post exclusivity.
In 2025, revenue totaled $61 billion with $44 billion gross profit and a 35% operating margin supporting pipeline investment.
For 2026, guidance targets $67 billion revenue and $14 to $15 adjusted EPS, with margins nearing 49% despite ongoing Humira pressure.
“We recently announced a voluntary agreement with the U.S. government… committing $100 billion in U.S. R&D and capital investments over the next decade,” CEO Rob Michael on Q4 2025 earnings call.
Recent developments include January 2026 oncology deal activity tied to RC148 and February 2026 regulatory filings for Rinvoq in vitiligo, while Epkinly’s Phase 3 update highlighted progress alongside durability debates in lymphoma outcomes.
At $223 versus a $291 model value using a 15x multiple, valuation hinges on pipeline execution sustaining the revenue base.
What the Model Says for ABBV Stock
AbbVie’s diversified franchises and post Humira transition support stable cash generation but limit upside given capital intensity.
The model assumes 8.3% revenue growth, 47.1% operating margins, and a 15.1x exit multiple, producing a $291.11 target price.
This equates to 30.3% total upside from $223.43 and a 9.5% annualized return over roughly three years.
Given a 9.5% annualized return below typical equity hurdles, the model signals a Sell on risk adjusted grounds.
With a modeled 9.5% annualized return below a 10% equity hurdle, compensation favors capital preservation over appreciation, justifying a Sell on valuation discipline.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for AbbVie stock:
1. Revenue Growth: 8.3%
AbbVie stock delivered 8.6% revenue growth over the last year, reflecting a large pharmaceutical base transitioning beyond Humira while sustaining scale across immunology and neuroscience.
Current execution supports 8.3% growth as Skyrizi and Rinvoq offset Humira erosion, with total revenue expanding from $56 billion to $61 billion during the most recent cycle.
Forward results require continued immunology momentum and stable pricing, while setbacks in regulatory timing or competitive intensity would pressure the growth stack rapidly.
This is below the 1-year historical revenue growth of 8.6%, indicating the model assumes modest deceleration consistent with portfolio maturity rather than sustained acceleration.
2. Operating Margins: 47.1%
AbbVie stock’s operating margin averaged 41.4% over the last year, reflecting heavy R&D spending alongside integration costs and post Humira restructuring.
The model assumes margin expansion to 47.1% as revenue scales to $67 billion and operating income grows faster than operating expenses.
This outcome depends on disciplined cost control and pipeline efficiency, while execution misses or reinvestment creep would compress margins materially.
This is above the 1-year historical operating margin of 41.4%, indicating the model assumes improved efficiency that requires sustained execution discipline.
3. Exit P/E Multiple: 15.1x
The exit P/E multiple capitalizes AbbVie stock’s terminal earnings durability after the growth transition stabilizes and pipeline visibility improves.
A 15.1x multiple reflects normalized sentiment for a large pharmaceutical company with mid single digit growth and high cash flow conversion.
Because margin expansion and growth are already embedded, any earnings disappointment would lead to multiple compression rather than re-rating support.
This is below the 1-year historical P/E multiple of 16.4x, indicating the model assumes valuation normalization rather than expansion at maturity.
What Happens If Things Go Better or Worse?
AbbVie stock’s performance hinges on immunology execution, pipeline delivery, and post Humira portfolio stability, creating distinct operating paths through 2030.
- Low Case: If competitive pressure persists and cost discipline weakens, revenue grows around 5.0% and net margins hold near 38.6% → 4.6% annualized return.
- Mid Case: With core franchises performing steadily, revenue growth near 5.5% and net margins improving toward 40.9% → 8.9% annualized return.
- High Case: If immunology and neuroscience outperform while costs scale efficiently, revenue reaches about 6.1% and net margins approach 42.7% → 12.6% annualized return.
How Much Upside Does AbbVie Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
